A Phase 3 interventional study of insulin degludec/insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 73 sites in 15 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 7 in phase 3, and was the 23rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 362 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 39 interventional studies. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 39 have an industry lead sponsor. The 9 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 28th largest by enrollment of the 149 interventional ones that give a count, is one of 14 that started in 2013, is one of 54 in phase 3, and was the 153rd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 362 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Subjects diagnosed with type 1 diabetes mellitus - below or equal to 11.0% Exclusion Criteria: - Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the investigator - More than 1 episode of diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1 (Screening) - Any chronic disorder or significant concomitant disease, which in the investigator's opinion might jeopardise the subject's safety or compliance with the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart · Drug: insulin aspart
Drug: insulin detemir · Drug: insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
Administered s.c. with the remaining meals. Dose individually adjusted.
Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
Administered s.c. at meal-times. Dose individually adjusted.
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.
Time frame: Week 0 to week 16
Change From Baseline in Fasting Plasma Glucose
Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.
Time frame: week 0, week 16
Incidence of Treatment Emergent Adverse Events (TEAEs)
A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.
Time frame: After 16 weeks of treatment
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)
Treatment emergent hypoglycaemic episodes (PG \< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia). Confirmed hypoglycaemic episodes were defined as episodes that were either: 1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or 2. An episode biochemically confirmed by PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
Time frame: After 16 weeks of treatment
Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes
The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint
Time frame: After 16 weeks of treatment
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill
The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.
Time frame: After 16 weeks of treatment
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)
The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L
Time frame: After 16 weeks of treatment
The trial was conducted at 63 sites in 14 countries as follows: Belgium: 3 sites; Brazil: 1 sites; Canada: 3 sites; Czech Republic 3 sites; Croatia: 2 sites; Israel: 6 sites; Macedonia: 2 sites; Poland: 3 sites; Russia: 5 sites; Serbia: 4 sites; Slovenia: 1 sites; South Africa: 2 sites; Spain: 5 sites; and United States: 23 sites.
| Milestone | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Started | 182 | 180 |
| Exposed | 181 | 179 |
| Completed | 174 | 168 |
| Not completed | 8 | 12 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Withdrawal by subject | 6 | 10 |
| Withdrew: Protocol violation | 1 | 0 |
Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.
| percentage (%) | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) | -0.3 ± 1.0 | -0.3 ± 0.9 |
Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.
| mmol/L | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose | -0.3 ± 6.4 | -0.1 ± 4.8 |
A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.
| number of events | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) | 501 | 460 |
Treatment emergent hypoglycaemic episodes (PG \< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia). Confirmed hypoglycaemic episodes were defined as episodes that were either: 1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or 2. An episode biochemically confirmed by PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
| episodes | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia) | 2532 | 2672 |
The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint
| episodes | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes | 316 | 291 |
The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.
| episodes | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill | 599 | 449 |
The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L
| episodes | IDegAsp OD | IDet OD/BID |
|---|---|---|
| Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L) | 6 | 12 |
Collected over Onset date on or after the first day of esxposure to randomised treatment and no later than 7 days after the last day on randomised treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp OD | — | 11/181 (6.1%) | 96/181 (53%) |
| IDet OD/BID | — | 7/179 (3.9%) | 97/179 (54.2%) |
| Event | IDegAsp OD | IDet OD/BID |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 5/181 | 1/179 |
| FallInjury, poisoning and procedural complications | 0/181 | 1/179 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 1/181 | 1/179 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/181 | 1/179 |
| Loss of consciousnessNervous system disorders | 0/181 | 1/179 |
| LaryngitisInfections and infestations | 0/181 | 1/179 |
| Viral infectionInfections and infestations | 1/181 | 1/179 |
| Fibula FractureInjury, poisoning and procedural complications | 1/181 | 0/179 |
| Tibia FractureInjury, poisoning and procedural complications | 1/181 | 0/179 |
| Compartment syndromeMusculoskeletal and connective tissue disorders | 1/181 | 0/179 |
| Event | IDegAsp OD | IDet OD/BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 36/181 | 32/179 |
| HeadacheNervous system disorders | 23/181 | 32/179 |
| VomitingGastrointestinal disorders | 22/181 | 12/179 |
| Abdominal pain upperGastrointestinal disorders | 14/181 | 17/179 |
| Upper respiratory tract infectionInfections and infestations | 11/181 | 17/179 |
| PyrexiaGeneral disorders | 17/181 | 10/179 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/181 | 13/179 |
| coughRespiratory, thoracic and mediastinal disorders | 13/181 | 9/179 |
| InfluenzaInfections and infestations | 9/181 | 10/179 |
| PharyngitisInfections and infestations | 3/181 | 10/179 |
The Full Analysis set (FAS) included all randomised subjects.
| Age, Continuous(years) | IDegAsp OD | IDet OD/BID | Total |
|---|---|---|---|
| Mean | 10.5 ± 4.3 | 10.8 ± 4.6 | 10.6 ± 4.5 |
| Sex: Female, Male(Participants) | IDegAsp OD | IDet OD/BID | Total |
|---|---|---|---|
| Female | 93 | 94 | 187 |
| Male | 89 | 86 | 175 |
| HbA1c(percentage (%)) | IDegAsp OD | IDet OD/BID | Total |
|---|---|---|---|
| Mean | 8.1 ± 1.2 | 8.1 ± 1.2 | 8.1 ± 1.2 |
| Fasting plasma Glucose (FPG)(mmol/L) | IDegAsp OD | IDet OD/BID | Total |
|---|---|---|---|
| Mean | 8.6 ± 4.4 | 8.1 ± 4.2 | 8.4 ± 4.3 |
Ran from Oct 2013 to primary completion in Nov 2014, 12 months.
Results were first posted in Nov 2015, 1 year after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 12 months is below that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart